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RESEARCH ARTICLE Open Access
A 3D in vitro model of the human breast
duct: a method to unravel myoepithelial-
luminal interactions in the progression of
breast cancer
Edward P. Carter1*, James A. Gopsill2, Jennifer. J. Gomm1, J. Louise Jones1 and Richard P. Grose1*
Abstract
Background: 3D modelling fulfils a critical role in research, allowing for complex cell behaviour and interactions to be
studied in physiomimetic conditions. With tissue banks becoming established for a number of cancers, researchers now
have access to primary patient cells, providing the perfect building blocks to recreate and interrogate intricate cellular
systems in the laboratory. The ducts of the human breast are composed of an inner layer of luminal cells supported by an
outer layer of myoepithelial cells. In early-stage ductal carcinoma in situ, cancerous luminal cells are confined to the ductal
space by an intact myoepithelial layer. Understanding the relationship between myoepithelial and luminal cells in the
development of cancer is critical for the development of new therapies and prognostic markers. This requires the
generation of new models that allows for the manipulation of these two cell types in a physiological setting.
Methods: Using access to the Breast Cancer Now Tissue Bank, we isolated pure populations of myoepithelial and luminal
cells from human reduction mammoplasty specimens and placed them into 2D culture. These cells were infected with
lentiviral particles encoding either fluorescent proteins, to facilitate cell tracking, or an inducible human epidermal growth
factor receptor 2 (HER2) expression construct. Myoepithelial and luminal cells were then recombined in collagen gels, and
the resulting cellular structures were analysed by confocal microscopy.
Results: Myoepithelial and luminal cells isolated from reduction mammoplasty specimens can be grown separately in
2D culture and retain their differentiated state. When recombined in collagen gels, these cells reform into physiologically
reflective bilayer structures. Inducible expression of HER2 in the luminal compartment, once the bilayer has formed, leads
to robust luminal filling, recapitulating ductal carcinoma in situ, and can be blocked with anti-HER2 therapies.
Conclusions: This model allows for the interaction between myoepithelial and luminal cells to be investigated in an
in-vitro environment and paves the way to study early events in breast cancer development with the potential to act
as a powerful drug discovery platform.
Background
The ducts of the human breast are composed primarily of
two cellular elements in a bilayer structure: luminal
epithelial cells, which form a polarised layer around the
central ductal cavity, and myoepithelial cells that are posi-
tioned between the basement membrane and the luminal
epithelial layer. These myoepithelial cells secrete extracel-
lular matrix components required for the correct polarity
of the luminal cells and also contract during lactation in
order to propel milk through the ductal tree [1, 2].
An intriguing relationship between these two cell types
is observed in ductal carcinoma in situ (DCIS). DCIS is
characterised by a proliferation of neoplastic luminal cells
into the luminal space of the breast duct, whereas the
outer ring of myoepithelial cells remains intact. Accord-
ingly, many have proposed that DCIS is a precursor to
invasive breast cancer [3, 4]. However, as many as 50% of
DCIS cases will not develop into invasive breast cancer
[5, 6]. Combined with earlier detection of DCIS, there
has been a rise in potential overdiagnosis of breast
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cancer and, as a consequence, potentially unnecessary
treatment [7]. Novel prognostic markers are therefore
needed to identify which cases of DCIS will progress to
invasive cancer and which will remain benign. Putative
markers are likely to reflect either a loss of myoepithe-
lial integrity, which facilitates subsequent cancer cell
invasion, or an alteration in the myoepithelial pheno-
type [8]. Moreover, deeper understanding of how the
myoepithelial cells maintain the polarised luminal sur-
face, as well as how the relationship between luminal
and myoepithelial cells alters with tumour evolution, is
key to understanding early mechanisms of cancerous
transformation in the breast.
2D cell culture is the primary tool for cancer researchers
because this technique provides a standardised high-
throughput system whereby the characteristics of specific
cell types can be dissected and compared with those of
other researchers across the world. However, this is largely
reliant on cancer cell lines that do not adequately recap-
itulate the complexity of the cancer environment [9]. 3D
culture systems are more advantageous because they bet-
ter reflect the environment in vivo and allow the impact
of the extracellular matrix to be assessed. For instance, a
number of breast epithelial cell lines, such as MCF-10A
cells, are able to form spheroids of polarised epithelial
cells with luminal centres, similar to breast duct morph-
ology, when placed in extracellular matrix gels [10–12].
However, a caveat to these systems is that there is no true
bilayer structure, thus preventing dissection of the
myoepithelial-luminal cell relationship.
Tissue banks for cancer research are becoming increas-
ingly accessible (e.g., http://breastcancertissuebank.org),
providing researchers with access to normal as well as
tumour-derived patient cells. These invaluable resources
require new methodologies and models to maximise their
potential benefit for research and patients. Using cells de-
rived from normal human breast tissue, we have devel-
oped a novel 3D model of the human breast duct bilayer
for research applications. We demonstrate that our model
is more reflective of the human breast duct than current
models and highlight its translational utility by adapting a
lentiviral engineering approach to allow objective evalu-
ation of early-stage breast cancer.
Results
Primary human myoepithelial and luminal cells maintain
their characteristics in vitro
To adequately investigate the relationship between myoe-
pithelial and luminal cells, these two cell populations first
need to be separated and cultured individually to allow for
their genetic manipulation prior to rebuilding the duct
in vitro (Fig. 1a). These two cell types were separated from
ductal organoids isolated from patients who had under-
gone reduction mammoplasty, based on their expression
of CD10 and epithelial cell adhesion molecule (EpCAM),
for myoepithelial and luminal cells, respectively (Fig. 1b).
Luminal and myoepithelial cells can be maintained and
proliferate in specific culture medium and exhibit distinct
morphologies (Fig. 1c). It has been suggested that the
mouse mammary gland contains adult stem cells that can
proliferate into both cell types of the ductal tree [13, 14].
We therefore assessed whether our cultures of purified
myoepithelial and luminal cells maintained their differenti-
ated phenotypes in culture. Following 10 days of 2D
culture, myoepithelial cells expressed the myoepithelial
markers calponin, cytokeratin (CK) 14 and p63 and showed
no expression of the luminal markers CK8 and CK19
(Fig. 1d, e). The converse was found with cultured luminal
cells. It was noted that a few luminal cells expressed low
levels of CK14. The appearance of CK14-positive luminal
cells has, however, been reported in the normal human
breast duct [15]. We suspect this small CK14-positive
population simply reflects the heterogeneity of the luminal
cells extracted from our preparations. Whereas luminal
cells could be maintained in culture for 3 weeks before
becoming senescent, myoepithelial cells could be cultured
for up to 8 weeks, and during this time, both cell types
retained their characteristics. Overall, our analysis suggests
that neither cell type transdifferentiates while in culture.
Myoepithelial and luminal cells form physiologically
reflective ductal structures in 3D collagen gels
To examine the fate of these two cell types in 3D gels, we
introduced genetic constructs for fluorescent proteins into
the cells prior to their recombination. Mixed cultures of
breast epithelial cells have been shown to be particularly
resistant to lentiviral infection [16]. Indeed, we observed
the same resistance to lentiviral infection in our individual
cultures of myoepithelial and luminal cells, with negligible
expression of fluorescent proteins upon exposure to
azurite lentiviral particles (Fig. 2a). Lentiviral infection was
substantially increased by pre-treating the virus with
neuraminidase prior to the application of particles to cells
(Fig. 2a) [16]. To effectively manipulate transgene expres-
sion in these primary cells, it is important to ascertain the
most efficient promoters that can be used. We examined
the ability of several common promoters (CMV, EF1α,
CAG, PGK and UBC) to drive green fluorescent protein
(GFP) expression in both luminal and myoepithelial cells.
While cytomegalovirus (CMV) was able to drive signifi-
cant protein expression in both cell types, all other
promoters were very weak (Additional file 1: Figure S1).
3D culture models use a variety of matrix substrates to
facilitate the growth of cellular structures. Matrigel, a solu-
bilised basement membrane preparation extracted from
Engelbreth-Holm-Swarm mouse sarcoma cells, and rat-tail
collagen are two of the most common matrices used for
3D culture. We therefore decided to test both types of
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Fig. 1 Isolated myoepithelial and luminal cells maintain their characteristics in vitro. a Schematic of proposed ductal model. b Representative
fluorescence-activated cell sorting plots of reduction mammoplasty specimens separated by expression of CD10 (allophycocyanin fluorescence,
blue gate) and epithelial cell adhesion molecule (EpCAM; phycoerythrin fluorescence, green gate). c Representative light micrographs of isolated
myoepithelial and luminal cells grown in vitro for 10 days. Images taken at × 4 original magnification. Scale bar = 100 μm. d and e Western blot
(d) and confocal (e) analysis of calponin, p63, cytokeratin (CK) 14, CK8 and CK19 expression in myoepithelial and luminal cells grown for 10 days
in culture. Cell nuclei are labelled with 4′,6-diamidino-2-phenylindole (blue). Images and plots are representative of cells derived from at least three
donors. Scale bar = 20 μm
Carter et al. Breast Cancer Research  (2017) 19:50 Page 3 of 10
matrices for ductal re-formation using isolated luminal and
myoepithelial cells. Our fluorescence-activated cell sorting
(FACS) analysis confirmed previous data indicating that
myoepithelial and luminal cells exist at a 1:1 ratio in the
normal human breast ducts (Fig. 1b) [17]. Cultured myoe-
pithelial and luminal cells were added to 3D gels at this
ratio to best mimic the physiological state. When placed as
a mixture of single cells into collagen gels, spheroid and
elongated ductal structures were formed by 10 days of
culture, which became more complex by day 21. Matrigel-
based gels, however, supported only spheroid formation
(Fig. 2b).
Using GFP-labelled myoepithelial cells and azurite blue-
labelled luminal cells in collagen-based gels, we observed
that these two cell types began to coalesce by 3 days of
culture. By 7 days, defined structures had formed, with
myoepithelial cells forming an outer ring around an inner
core of luminal cells, which became more complex by day
21 (Fig. 2c). Myoepithelial cells were observed to adopt an
elongated morphology along the ducts, recapitulating
their native state. Conversely, when placed in Matrigel,
myoepithelial and luminal cells formed spheres comprised
of cell types in no defined arrangement (Fig. 2d).
We next determined the composition of the structures
formed by examining the expression of myoepithelial and
luminal markers and comparing these with normal human
sections. Spheroids and ducts formed in collagen gels con-
sisted of an inner ring of cells expressing luminal markers
(CK8, EpCAM) surrounding a central luminal cavity. This
inner layer was surrounded by an outer layer expressing
markers of myoepithelial cells (P-cadherin, vimentin), con-
sistent with the bilayer seen in normal human duct sections
(Fig. 3). The cells comprising spheroids formed in Matrigel
expressed both myoepithelial and luminal markers and
lacked a bilayer configuration (Additional file 1: Figure S2).
HER2 overexpression destabilises ductal bilayer
This model of the ductal bilayer allows for the manipula-
tion of either cell type prior to recombination. We
wished to examine whether this model could be used to
study prominent drivers of breast cancer in a more
physiological human context. Human epidermal growth
factor receptor 2 (HER2) overexpression is found in
approximately 30% of invasive breast cancers and is as-
sociated with aggressive disease progression [18]. HER2
is also overexpressed in many high-grade DCIS lesions.
Although the HER2-targeted therapies, such as trastuzu-
mab and lapatinib, are effective in the clinic [18, 19],
many patients do not respond to treatment, and as many
as 70% will develop resistant cancers [20]. Thus, there is
Fig. 2 Myoepithelial and luminal cells are susceptible to lentiviral infection and re-form into spheroid and ductal structures in collagen-based gels. a Azurite
blue expression in myoepithelial and luminal cells 48 h following lentiviral delivery with or without neuraminidase (20 mU/ml) pre-treatment. Scale bar =
20 μm. b Representative bright-field images of isolated myoepithelial and luminal cells grown together for 21 days in collagen- or Matrigel-based gels.
Scale bar = 200 μm. c and d Representative confocal images of green fluorescent protein-labelled myoepithelial and azurite blue-labelled luminal cells
grown in collagen-based (c) or Matrigel-based (d) gels. Images are representative of cells derived from at least three donors. Scale bar = 20 μm
Carter et al. Breast Cancer Research  (2017) 19:50 Page 4 of 10
a need to interrogate the biology of HER2-driven cancers
to help overcome acquired resistance.
Fine control of gene expression is essential for its study
in complex 3D models; stable overexpression of HER2
would allow for only its role in the formation of model
bilayer to be studied, whereas inducible titred expression
allows for change in gene expression to be assessed once a
model bilayer has formed, mimicking the progression of
breast cancer. We therefore constructed an inducible
HER2 expression construct based on the pINDUCER
system [21]. Expression of HER2 was induced readily and
efficaciously in infected luminal cells upon exposure of
the cells to doxycycline (Fig. 4a).
HER2-inducible luminal cells were combined with un-
altered myoepithelial cells in collagen gels and cultured
for 14 days, in which time ductal structures appear.
Doxycycline, with or without trastuzumab, was then
added to cultures for the remaining 7 days to induce
HER2 expression. Control structures exhibited intact bi-
layer formation and a hollow luminal centre (Fig. 4b).
Conversely, ducts treated with doxycycline for the final
7 days of culture exhibited significant luminal filling,
with clear overexpression of HER2 in luminal cells com-
pared with controls (Fig. 4b). Further, an intact myoe-
pithelial layer was still evident in these cultures, as
evidenced by an outer layer of vimentin-expressing cells
(Fig. 4d). This expression pattern recapitulates that ob-
served in HER2+ DCIS samples (Fig. 4d).
To objectively quantify luminal filling, we calculated
the volume of cells within representative spheres and
compared this with the calculated volume for the entire
structure, and luminal filling would be signified by a sig-
nificantly higher cell volume/total volume ratio than
structures with complete lumen (Additional file 1: Figure
S3). We observed a significant increase in cell/total vol-
ume ratio when this strategy was applied to cultures
treated with doxycycline compared with untreated con-
trols (Fig. 4c).
Strikingly, co-treatment with doxycycline and the
HER2-targeted antibody trastuzumab prevented luminal
filling, despite the overexpression of HER2 in the luminal
compartment (Fig. 4b). This is further demonstrated by a
Fig. 3 Spheroid and ductal structures formed in collagen gels recapitulate a physiological breast bilayer. Expression of cytokeratin (CK) 8, P-
cadherin, epithelial cell adhesion molecule (EpCAM) and vimentin spheroid (a) and ductal (b) structures formed from myoepithelial and luminal
cells grown in collagen for 21 days. Representative images from sections of normal human breast ducts (a and b) are also presented. Cell nuclei
are labelled with 4′,6-diamidino-2-phenylindole (blue). Scale bar = 20 μm. Images are representative of structures formed from cells derived from
at least three donors
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Fig. 4 Overexpression of human epidermal growth factor receptor 2 (HER2) in the luminal compartment of a bilayer model results in destabilisation of
the bilayer and luminal filling. a HER2 expression in luminal cells infected with inducible HER2 lentiviral particles and cultured in 0.01, 0.1 or 1 μg/ml
doxycycline (DOX) for 48 h. b Representative z-sections of 4′,6-diamidino-2-phenylindole (DAPI)-labelled nuclei (upper panels) and HER2 expression
(lower panels) of ductal spheroids following 14 days of culture plus 7 further days with (middle panel) or without (left panel) 1 μg/ml DOX treatment.
Alternatively, DOX-treated cultures were also treated with 10 μg/ml trastuzumab for the final 7 days of culture (right panel). Scale bar = 20 μm. c
Quantification of spheroids following treatment presented as ratio of total cell volume to total sphere volume. d HER2 and vimentin expression in
representative HER2-expressing ductal spheroids and ductal carcinoma in situ breast sections. Cell nuclei are labelled with DAPI (blue). Scale bar =
20 μm. Data are presented as mean ± SD. Images are representative of structures formed from cells derived from at least three donors. ** P < 0.01
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significant reduction in cell/total volume of co-treated
structures compared with doxycycline alone (Fig. 4c).
Discussion
3D models are becoming increasingly commonplace as
the technologies and associated imaging techniques be-
come more accessible to researchers [22]. Complex
models such as these require building blocks that best
resemble the tissue they seek to mimic. Cancer cell lines
in 3D environments are very useful for answering basic
biological questions, but they are of little use when mod-
elling the complex tumour architecture because many
cell lines do not adequately reflect the tumour they
purport to represent [9, 12]. Furthermore, they typically
represent late-stage disease and not early disease and its
interaction with components of the microenvironment.
Primary cells derived from patient samples are the
perfect resource for complex 3D models that seek to
represent the normal and progressive tumour environ-
ment. We have demonstrated that normal myoepithelial
and luminal cells can be isolated from reduction mam-
moplasty specimens and maintain their differentiated
state in traditional 2D cultures. Recombined into a 3D
environment, these cells reorganise into a native bilayer
structure. This is a unique strength of our system
compared with those that use common cell lines such as
MCF10A cells, which can form spheroids with myoe-
pithelial and luminal characteristics but lack a bilayer ar-
rangement of cells.
The 3D environment in which the cellular components
reside is a critical component of any model and modifies
the resulting structure and behaviour. Our model high-
lights the importance of using an appropriate matrix
where collagen-based gels promoted the re-formation of a
bilayer from isolated myoepithelial and luminal cells,
whereas Matrigel did not. Matrigel is rich in laminin,
which is required for correct luminal orientation in the
breast [23]. Myoepithelial cells are a major source of lam-
inin in the breast [24]; therefore, in a Matrigel environ-
ment, there is no incentive for the two cell types to come
together. However, in collagen, the luminal cells require
myoepithelially expressed laminin, thus promoting their
coalescence into co-units. It is intriguing that the cells in
Matrigel cultures adopted characteristics of both myoe-
pithelial and luminal cells. This would suggest that one of
the many components of Matrigel is sufficient to drive the
plasticity of these cells, which may have implications for
the use of Matrigel in primary cell-based work.
Overexpression of HER2 in the luminal component of
our bilayer model resulted in the destabilisation of the
bilayer and filling of the luminal centre. The breakdown in
epithelial orientation in response to overexpression of
HER2 has been documented in cancer cell lines [25]. Strik-
ingly, this loss of lumen could be blocked with HER2-
targeted therapy. This proof of concept establishes the use
of this model as a screen for novel therapies, not only for
HER2-driven cancer but also potentially for any breast can-
cer subtype, given appropriate manipulation of the cellular
components. Intriguingly, the outer myoepithelial layer of
our model remained intact following HER2 overexpression
in the luminal compartment, recapitulating the develop-
ment of DCIS. Furthermore, this model can be modified to
recapitulate the heterogeneity present in breast tumours.
Heterogeneity within breast tumours accounts for variation
in treatment response and the emergence of therapy-
resistant tumours. Current animal- and cell-based models
of breast cancer inherently model a homogeneous tumour
and therefore are inadequate to study this crucial compo-
nent of breast cancer [26]. The ability to objectively quan-
tify luminal filling is a significant strength of this model
because it demonstrates the reproducibility of our model
between patient samples and confirms the appropriateness
of this model for semi-high-throughput applications.
Conclusions
A number of groups have developed complementary 3D
models of the human breast duct from primary human
cells, highlighting the need for such models in research
[27–29]. The critical advantage of our model is the ability
to isolate the individual cell types of the breast duct and
modify them as desired before recombining them in 3D to
re-create a physiologically reflective duct. This model has
the potential to facilitate the dissection of cellular crosstalk
in the breast and illuminate the relationship between myoe-
pithelial and luminal cells in the progressive stages of breast
cancer. Moreover, this offers a powerful and unique tool to
understand the biology of DCIS and potential therapeutic
approaches, which are essential to developing more tailored
therapy for this poorly understood disease.
Methods
Cell isolation and culture
Ductal organoids from reduction mammoplasty specimens
were obtained from the Breast Cancer Now Tissue Bank
(REC 15/EE/0192). Ductal organoids were digested to a
single-cell suspension through digestion in a 0.05% trypsin,
0.4 mg/ml DNase solution at 37 °C for 15 minutes as de-
scribed previously [30]. Pure populations of myoepithelial
and luminal cells were then isolated through either mag-
netic bead or FACS separation. Briefly, a single-cell suspen-
sion of cells derived from organoids was incubated at 4 °C
for 20 minutes with a mouse anti-human CD10 antibody
(catalogue number mca1556; Bio-Rad Laboratories, Oxford,
UK) conjugated to sheep anti-mouse immunoglobulin G
Dynabeads (Thermo Fisher Scientific, Paisley, UK) at a ratio
of 2:1 (cells/beads) to label myoepithelial cells. Tagged cells
were then pulled out through magnetic separation, and the
remaining cells were incubated with Epithelial Enrich
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Dynabeads (Thermo Fisher Scientific) for 20 minutes at
4 °C to label luminal cells.
Alternatively, for isolation by FACS, single cells derived
from organoids were resuspended at 20 × 106 cells/ml and
incubated with 0.25 μg/ml allophycocyanin (APC)-
conjugated mouse anti-human CD10 (catalogue number
332777; BD Biosciences, Oxford, UK) and 0.06 μg/ml
phycoerythrin (PE)-conjugated mouse anti-human EpCAM
(catalogue number 347198; BD Biosciences) antibodies for
45 minutes at 4 °C. Cells were then incubated with 0.1 μg/
ml 4′,6-diamidino-2-phenylindole (DAPI) to label dead
cells prior to the separation of myoepithelial and luminal
cells based on APC and PE fluorescence, respectively.
FACS separation was performed on a BD FACSAria II cell
sorter (BD Biosciences).
Isolated luminal cells were cultured in DMEM/F-12
medium (Sigma-Aldrich, Poole, UK) supplemented with
10% FBS, 0.5 μg/ml hydrocortisone (Sigma-Aldrich),
10 μg/ml apo-transferrin (Sigma-Aldrich), 5 μg/ml insu-
lin (Sigma-Aldrich) and 10 ng/ml epidermal growth fac-
tor (EGF; Sigma-Aldrich). Isolated myoepithelial cells
were cultured in HuMEC medium (Thermo Fisher Sci-
entific) supplemented with 0.5 μg/ml hydrocortisone,
5 μg/ml insulin, 10 ng/ml EGF and 50 μg/ml bovine pi-
tuitary extract (Thermo Fisher Scientific).
3D ductal culture
Primary myoepithelial and luminal cells were combined in
a 1:1 ratio and placed in collagen gels, consisting of 2 mg/
ml collagen type I (Corning Life Sciences, Flintshire, UK),
and 25 mM HEPES, prepared in luminal culture medium
adjusted to neutral pH with NaOH. Gels were allowed to
set at 37 °C before being overlaid with luminal culture
medium. Culture media and indicated drug treatments
were changed every 2–3 days. Alternatively, equal propor-
tions of myoepithelial and luminal cells were placed on a
pre-set bed of Matrigel Growth Factor Reduced (Corning
Life Sciences) and maintained in luminal culture medium
containing 5% Matrigel. Doxycycline was sourced from
Sigma-Aldrich. Trastuzumab was a kind gift from Roche
Pharma (Basel, Switzerland).
Immunofluorescence
Cells cultured on coverslips were fixed in 10% neutral
buffered formalin, permeabilised with 0.05% saponin and
blocked with 5% bovine serum albumin (BSA) prior to in-
cubation with primary antibody diluted in 5% BSA. Sam-
ples were incubated subsequently in a species-appropriate
fluorescent secondary antibody before being mounted.
Collagen gels were first treated with 1 mg/ml collage-
nase (Sigma-Aldrich) for 10 minutes at 37 °C prior to
fixation in 10% neutral buffered formalin. Gels were then
permeabilised overnight with 1% Triton X-100 and
blocked in 10% FBS/2% BSA. Gels were then incubated in
primary antibodies for 48 h, followed by a 2-h incubation
with species-appropriate fluorescent secondary antibody
prior to mounting. Where indicated, gels were incubated
in 1 μg/ml DAPI prior to mounting to label cell nuclei.
Paraffin-embedded sections of normal and DCIS breast
tissue samples were obtained from the Breast Cancer Now
Tissue Bank (REC 15/EE/0192). Sections were de-waxed,
and antigen retrieval was performed though boiling sec-
tions with 10 mM sodium citrate buffer, pH 6.0. Sections
were subsequently permeabilised in 0.1% Triton X-100
and blocked with 10% FBS/2% BSA. Sections were then
incubated in primary antibodies as indicated above prior
to secondary incubation in a species-appropriate fluores-
cent antibody. Prior to mounting, sections were incubated
with 1 μg/ml DAPI to label cell nuclei.
Primary antibodies used were CK19 (catalogue number
RB-9021; NeoMarkers/Thermo Fisher Scientific, Fremont,
CA, USA), EpCAM (catalogue number MA5-12436;
Thermo Fisher Scientific), p63 (catalogue number SC-
8431; Santa Cruz Biotechnology, Dallas, TX, USA), vimen-
tin (catalogue number HPA001762; Atlas Antibodies,
Bromma, Sweden), P-cadherin (catalogue number 2198 s;
Cell Signaling Technology, Danvers, MA, USA), HER2
(catalogue number 2165 s; Cell Signaling Technology),
CK14 (catalogue number ab51054; Abcam, Cambridge,
UK), CK8 (catalogue number C5301; Sigma-Aldrich), cal-
ponin (catalogue number ABT129; EMD Millipore,
Watford, UK) and vimentin (catalogue number M0725;
Dako, Carpinteria, CA, USA). Secondary antibodies used
were Alexa Fluor 488 donkey anti-mouse (catalogue num-
ber A21202; Life Technologies) and Alexa Fluor 555 don-
key anti-rabbit (catalogue number A31572; Life
Technologies). Fluorescent images were acquired using a
Carl Zeiss LSM710 confocal microscope (Carl Zeiss Mi-
croscopy, Thornwood, NY, USA).
Immunoblotting
Cells lysates were prepared in 50 mM Tris-HCl,
150 mM NaCl, 1% Nonidet P40 buffer supplemented
with protease (EMD Millipore) and phosphatase (EMD
Millipore) inhibitor cocktails. Proteins were separated on
a 10% SDS-PAGE gel, transferred onto a nitrocellulose
membrane and blocked in 5% milk before being incu-
bated in primary antibody diluted 1:1000 in 5% BSA.
Membranes were then incubated with a species-
appropriate HRP-conjugated secondary antibody (Dako)
before bands were visualised using an enhanced chemilu-
minescence detection kit (GE Healthcare Life Sciences,
Piscataway, NJ, USA). In addition to the primary antibodies
listed above, the antibody HSC70 (catalogue number sc-
7298; Santa Cruz Biotechnology) was used. HRP-linked
secondary antibodies used were goat anti-mouse (catalogue
number P0447; Dako) and goat anti-rabbit (catalogue num-
ber P0448; Dako).
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Lentiviral cloning and production
An inducible HER2 expression vector was constructed
by subcloning the ERBB2 open reading frame from
pDONR223-ERBB2 (23888; Addgene, Cambridge, MA,
USA) into pINDUCER21 (46948; Addgene) using the
Gateway LR Clonase kit (Thermo Fisher Scientific)
following the manufacturer’s guidelines. Lentiviral parti-
cles were generated by co-transfecting HEK293T cells
with the packaging plasmids pMD2.G (12259; Addgene)
and pCMVR8.2 (12263; Addgene) and either pLV-GFP
(36083; Addgene), pLV-Azurite (36086; Addgene) or
pINDUCER21-ERBB2 using FuGENE HD transfection
reagent (Promega, Madison, WI, USA) following the
manufacturer’s guidelines. Virus-containing supernatant
was collected 48 h post-transfection.
When primary myoepithelial and luminal cells were
infected with lentiviral particles, particles were treated
with 20 mU/ml neuraminidase (Sigma-Aldrich) at 37 °C
for 30 minutes prior to their addition to cells. Particles
provided with SMARTchoice promoter selection plates
(GE Dharmacon, Lafayette, CO, USA) were also treated
with 20 mU/ml neuraminidase prior to their application
to cells; fluorescence intensity values were acquired
using a FLUOstar Omega fluorescent plate reader (BMG
Labtech, Cary, NC, USA).
Image analysis
To objectively and systemically quantify the spheroid
volume, a customised eight-step image analysis process
was developed. Z-sections of DAPI-labelled cells were
converted into greyscale and used to build the greyscale
distribution profile for the set of images. A threshold
indicating whether a pixel in the image relates to a cell
is then calculated; using this, z-sections are further proc-
essed into binary images that indicate cell presence. The
pixels indicating cells are then extracted and translated
into a geometrically accurate point cloud using original
image resolution values.
The generated point cloud contains the spheroid
volume of interest, cells that exist outside the spheroid
and potential noise from the data capture. To determine
the points that represent the spheroid volume of inter-
est, density-based spatial clustering of applications with
noise was employed. This detects clusters of points
within the 3D space with the largest cluster in terms of
the number of points being the spheroid volume. These
points are extracted to form the final point cloud. The
alpha-shape algorithm is then applied to form triangu-
lated bodies that represent the cell and spheroid
volumes. The algorithm requires selection of the alpha
radius to compute the bodies, and this parameter was
calculated as a function of the image resolution. Using
the triangulated bodies, the cell and spheroid volumes
are calculated alongside the resultant cell/body ratio.
Initial image analysis was performed using the Python
programming language and the Python Imaging Library,
SkLearn, NumPy and Matplotlib libraries. The alpha-
shape algorithm was performed using MATLAB software
and the Computational Geometry toolbox (MathWorks,
Natick, MA, USA).
Statistical analysis
Change in volume ratio between indicated treatments was
compared by analysis of variance followed by Tukey’s post
hoc test using Prism 5 software (GraphPad Software, La
Jolla, CA, USA).
Additional file
Additional file 1: Supplementary material. Figure S1. Promoter
efficacy in primary cultures of myoepithelial and luminal cells. a
Representative images of GFP expression in myoepithelial and luminal
cells 48 h following infection with neuraminidase-treated lentiviral particles
driving GFP expression under either human/mouse CMV, human/mouse
EF1α, CAG, PGK and UBC promoters. Scale bar = 20 μm. b Mean fluorescence
intensity (MFI) values of myoepithelial and luminal cells 48 h post-infection
with lentiviral particles as in (a). Images and values are representative of cells
derived from two donors. Figure S2. Spheroids formed in Matrigel cultures
express markers of both luminal and myoepithelial cells. Expression of
cytokeratin (CK) 8 and P-cadherin in spheroids formed in Matrigel from co-
culture of isolated myoepithelial and luminal cells over 21 days. Images are
representative of cells derived from at least three donors. Scale bar = 20 μm.
Figure S3. Objective and systematic calculation of cell and spheroid
volumes. Representative workflow of spheroid analysis. Raw DAPI z-sections
(a) are converted into greyscale images and a greyscale distribution profile
(b). Greyscale images are then converted to binary images using a calculated
threshold to indicate cell presence (c). The pixels that indicate cells are then
translated into a geometrically accurate point cloud using the known image
resolutions (d). Further post-processing using density-based spatial clustering
of applications with noise (DBSCAN) is performed to identify the main body
of cells (e). The point cloud representing the main spheroid is then extracted
(f). The alpha-shape algorithm is applied using thresholds set as a function of
the image resolutions to form triangulated bodies that represent the cells
and body (g). The volumes of these bodies are then calculated alongside the
resultant cell/body ratio. (PDF 1342 kb)
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